- Home
- ANIK
as 12-20-2024 3:30pm EST
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 255.6M | IPO Year: | 1993 |
| Target Price: | $24.50 | AVG Volume (30 days): | 95.2K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.83 - $29.12 | Next Earning Date: | 10-31-2024 |
| Revenue: | $164,168,000 | Revenue Growth: | 0.52% |
| Revenue Growth (this year): | -8.08% | Revenue Growth (next year): | -23.77% |
Latest Anika Therapeutics Inc. News
ANIK Breaking Stock News: Dive into ANIK Ticker-Specific Updates for Smart Investing
ACCESSWIRE
19 days ago
Sidoti Events, LLC's Virtual December Small-Cap Conference
GlobeNewswire
a month ago
Anika To Participate in December 2024 Investor Conferences
Simply Wall St.
2 months ago
Anika Therapeutics Third Quarter 2024 Earnings: Misses Expectations
GuruFocus.com
2 months ago
Anika Therapeutics Inc (ANIK) Q3 2024 Earnings Call Highlights: Strategic Shifts Amid Revenue ...
PR Newswire
2 months ago
Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics
Zacks
2 months ago
Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates
Associated Press Finance
2 months ago
Anika: Q3 Earnings Snapshot
GlobeNewswire
2 months ago
Anika Reports Third Quarter 2024 Financial Results
Compare ANIK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANIK Anika Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.